Glutamate Receptor Binding Sites in MPTP-Treated Mice

Abstract

Changes in excitatory amino acid (EAA) neurotransmission are thought to play an important role int he development of parkinsonian symptoms. We examined EAA receptor binding sites in substantia nigra, striatum, globus pallidus, and cortex at 2 weeks and 2 months after MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) injection in C57b16 mice. At 2 weeks striatal dopamine content in MPTP-treated mice was reduced to 7% of control and N-methyl- d-aspartate (NMDA)-sensitive [ 3H]glutamate and [ 3H]α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites were decreased in substantia nigra to 57 and 76% of control, respectively. In globus pallidus only [ 3H]AMPA binding sites were decreased to 80% of control; no significant changes were found in striatum or cortex. [ 3H]Kainate binding sites remained unchanged. At 2 months striatal dopamine content was reduced to 31% and no changes in EAA binding sites could be detected in any of the structures examined. [ 3H]Mazindol binding to striatal monoamine-uptake sties was decreased to 17% of control at 2 weeks versus 37% at 2 months. Our data indicate that modulation of NMDA and AMPA binding sites in substantia nigra and globus pallidus, the major projection areas of the subthalamic nucleus, takes place only after severe impairment of the nigrostriatal system.